In a landmark decision aimed at addressing one of the most persistent gaps in pediatric medicine, the U.S. Food and Drug Administration (FDA) has officially approved ViiV Healthcare’s Tivicay PD (dolutegravir) for the treatment of HIV-1 in newborns weighing at least 2 kg. This milestone marks the first time a second-generation integrase strand transfer inhibitor (INSTI) has been authorized for use in such a vulnerable patient population, offering a potent, well-tolerated therapeutic option where options were previously severely limited.
The approval represents a significant shift in the standard of care for perinatally exposed infants. By lowering the weight threshold to 2 kg (approximately 4.4 pounds) and removing the previous age restriction, the FDA has empowered clinicians to initiate life-saving antiretroviral therapy (ART) immediately following birth, a critical window for managing viral loads and improving long-term health outcomes for HIV-positive children.
The Clinical Necessity: Why Newborns Need Specialized Treatment
HIV remains a global health crisis, and the clinical needs of infants are distinct from those of adults. According to data from UNICEF, the stakes for untreated infants are dire: without timely access to antiretroviral therapy, approximately 50% of children living with HIV do not survive beyond their second birthday.
While perinatal transmission rates in the United States have been successfully suppressed to 1% or less through rigorous prenatal care and prophylactic measures, the infants who do test positive face a daunting path. For years, the lack of pediatric-specific formulations meant that neonates were often treated with older medications—drugs that were not specifically optimized for the unique metabolic pathways and physiological developmental stages of a newborn.
Tivicay PD, a dispersible tablet formulation, is designed to dissolve easily, allowing for precise dosing in infants who cannot swallow traditional pills. By incorporating this medication into early treatment regimens, physicians can now leverage the high barrier to resistance provided by dolutegravir, ensuring that the virus is suppressed effectively before it can cause irreversible immune system damage.
A Chronology of Progress: From Adult Approval to Neonatal Access
The journey to this expanded approval spans over a decade of rigorous clinical evaluation and regulatory review. The trajectory of dolutegravir’s evolution in pediatric medicine highlights the methodical approach required to bring life-saving drugs to the youngest patients.
- August 2013: The FDA grants its first approval for Tivicay (dolutegravir) for use in adults and adolescents aged 12 or older who weigh at least 40 kg (88.2 lbs). At this stage, the drug was recognized as a potent, well-tolerated integrase inhibitor, but data in younger children was still in the early stages of collection.
- 2020: Building on successful pediatric trials, the FDA approves the dispersible formulation, Tivicay PD. This iteration was authorized for children at least four weeks old who weighed at least 3 kg (6.6 lbs). This was a pivotal moment, as it allowed for more flexible dosing in young children, but a significant "gap" remained for newborns under four weeks old.
- 2025 (CROI): Preliminary results from the IMPAACT 2023 study are presented at the Conference on Retroviruses and Opportunistic Infections (CROI). These findings provide the essential evidence base regarding the safety and pharmacokinetics of dolutegravir in full-term infants, confirming that the drug could be safely administered in the first days of life.
- August 2026: The FDA grants final approval for the expanded indication, clearing the way for neonates weighing as little as 2 kg to receive the treatment from birth.
Supporting Data: The IMPAACT 2023 Study
The regulatory approval was underpinned by the NIH-funded IMPAACT 2023 study, a multicenter Phase 1 clinical trial that stands as a model for pediatric drug research. The trial enrolled 48 mother-infant pairs across sites in the United States, Thailand, and South Africa—regions where the burden of pediatric HIV is most acutely felt.
Pharmacokinetics and Tolerability
The primary objective of IMPAACT 2023 was to establish whether dolutegravir could safely reach therapeutic drug levels in newborns, whose liver and kidney functions are still maturing. Researchers found that the pharmacokinetic profile of the drug in newborns was remarkably consistent with the profiles seen in adults and older children.
In a specific cohort of 15 infants who underwent chronic dosing, researchers observed that infants weighing between 2.3 and 3.6 kg could successfully reach target drug concentrations using a 5-mg dispersible tablet. Dosing was initiated within the first five days of life, using an every-other-day schedule for the first two weeks before transitioning to daily administration. The safety data was equally encouraging; the side-effect profile was comparable to that observed in older pediatric populations, with no significant safety signals identified during the 16-week follow-up period.
Official Perspectives and Implications
The medical community has hailed the approval as a breakthrough in neonatal care. Dr. Diana F. Clarke, a professor at the Boston University School of Medicine and the lead investigator of the IMPAACT 2023 study, emphasized the long-standing void in the therapeutic landscape.
"For too long, newborns living with HIV have had too few treatment options designed and studied to meet their unique needs, despite the importance of starting treatment as early as possible," Dr. Clarke stated. Her sentiment reflects the broader frustration among pediatric infectious disease specialists who have long advocated for "age-appropriate" drug development.
The implications of this approval extend beyond simple convenience. By providing a reliable, standardized option for newborns, ViiV Healthcare is helping to normalize the early treatment of HIV, potentially reducing the mortality rate of infants who acquire the virus vertically. The integration of Tivicay PD into the standard-of-care antiretroviral cocktail for neonates will likely become the global benchmark for treatment protocols.
Commercial Context and the Future of ViiV’s HIV Portfolio
While the approval of Tivicay PD is a major clinical and humanitarian success, it also comes at a time when the broader HIV market is undergoing a transition. Commercially, the standalone Tivicay brand has seen its growth plateau as newer, long-acting therapies and combination regimens take center stage.
According to financial results released by GSK (the parent company of ViiV Healthcare), Tivicay sales reached £1.323 billion in 2025, a slight decline from the previous year. This performance is typical of a mature drug brand that has paved the way for more modern, convenient alternatives. However, the overall HIV portfolio remains a powerhouse for the company.
In 2025, GSK reported a total of £7.687 billion in HIV-related revenue, representing an 11% increase at constant exchange rates. This growth is largely driven by newer products such as the two-drug regimen Dovato and long-acting injectable therapies like Cabenuva and Apretude. These drugs have become the company’s primary growth engines, effectively offsetting the natural market saturation of older, daily-pill formulations.
The expansion of the Tivicay PD label is less about commercial dominance and more about cementing the drug’s legacy as a foundational component of pediatric HIV care. By securing this regulatory win, ViiV ensures that even as the market shifts toward long-acting injectables for adults, their foundational oral therapy remains the gold standard for the most delicate segment of the patient population.
Conclusion: A New Era for Pediatric HIV Care
The FDA’s decision to approve Tivicay PD for newborns is a triumph of collaborative research. It highlights what can be achieved when academic researchers, international health networks like IMPAACT, and pharmaceutical developers align their resources to focus on the needs of the most vulnerable.
As medical systems worldwide move to adopt these new guidelines, the focus will now shift to implementation and access. Ensuring that infants in low-resource settings—where the vast majority of pediatric HIV cases occur—have access to this dispersible formulation will be the next major challenge. Nevertheless, with a clear clinical roadmap and a proven, safe, and effective drug now available from birth, the global medical community is better equipped than ever to give infants living with HIV the best possible start in life.
About the Author
